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PEI-CHI WU: Will absence of GPAT1 improve diet-induced atherosclerosis in ApoE 
heterozygous mice? 
(Under the direction of Rosalind Coleman) 
 
This thesis separated into two parts.  The first part examined how the lack of GPAT 
affects atherosclerosis that depends on a western diet.  The second part examined 
whether the lack of GPAT does ameliorates the atherosclerosis developing on an 
atherogenic diet.    
In the first part, we fed ApoE+/-/GPAT1-/- mice and ApoE+/- mice on western diet for 4 
months.  We found that ApoE+/-/GPAT1-/- mice and ApoE+/- mice did not develop 
atherosclerotic lesions after 4 months of western diet.  ApoE+/-/GPAT1-/- mice had 
lower serum cholesterol, hepatic triacylglycerol and body weight than ApoE+/- mice.  
We could not conclude that ApoE+/-/GPAT1-/- mice could improve atherosclerosis.   
In the second experiment, we fed ApoE+/- and ApoE+/-/GPAT1-/-mice an atherogenic 
diet (15.8% fat, 1.25% cholesterol, 0.5% cholate) for 90 days.  We wanted to see if 
ApoE+/-/GPAT1-/- mice improve the diet-induced atherosclerosis on these ApoE+/-mice.  
We found out the ApoE+/-/GPAT1-/- mice increased their serum cholesterol and 
VLDL-cholesterol compared to ApoE+/- mice.  The atherosclerotic lesion sizes of 
ApoE+/-/GPAT1-/- mice and ApoE+/- mice were similar.  We concluded that the 
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absence of GPAT could not improve the diet-induced atherosclerosis.   
  
 iv 
 
TABLE OF CONTENTS 
TABLE OF CONTENTS ................................................................................................................ iv 
TABLE OF FIGURES .................................................................................................................... vi 
LIST OF ABBREVIATIONS .................................................................................................... viii 
Chapter 1 .......................................................................................................................................... 1 
Introduction ................................................................................................................................. 1 
1.1. Atherosclerosis .................................................................................................................... 1 
1.2. Plasma lipid metabolism ..................................................................................................... 3 
1.3. ApoE ..................................................................................................................................... 4 
1.4. Human apoE polymorphisms ............................................................................................. 5 
1.5. ApoE knockout mice ........................................................................................................... 6 
1.6. Influence of diets on the apolipoprotein E knockout mice. .............................................. 7 
1.7. GPAT .................................................................................................................................. 10 
1.7.1 GPAT isoforms ............................................................................................................ 10 
1.7.2. Difference of GPAT isoforms activities ..................................................................... 11 
1.7.3. Fatty acid preference of different GPAT isoforms ................................................... 12 
1.8. GPAT 1 knockout mice ..................................................................................................... 12 
Chapter 2 ........................................................................................................................................ 16 
Methods ..................................................................................................................................... 17 
Result and Discussion .............................................................................................................. 20 
Chapter 3 ........................................................................................................................................ 32 
Chapter 4 ........................................................................................................................................ 43 
Discussion ............................................................................................................................... 43 
Atherosclerosis ......................................................................................................................... 43 
Oxidative stress and atherosclerosis ...................................................................................... 45 
 v 
 
Adipose tissue effect ................................................................................................................ 47 
Reference ............................................................................................ Error! Bookmark not defined. 
 
  
 vi 
 
TABLE OF FIGURES 
 
 
TAB 2.1 WEIGHT AND PLASMA TRIACYLGLYCEROL AND PLASMA CHOLESTEROL IN APOE +/- 
FEMALE MICE AND APOE+/- /GPAT1-/- FEMALE MICE FED ON WESTERN DIETS FOR 120 
DAYS. ................................................................................................................. 23 
TAB 3.1 WEIGHT AND PLASMA TRIACYLGLYCEROL AND PLASMA CHOLESTEROL IN APOE +/- 
MICE, APOE+/- /GPAT1-/- MICE AND GPAT1-/- FEMALE MICE FED ON ATHEROGENIC 
DIETS FOR 90 DAYS. ............................................................................................ 37 
TAB 4.1 COMPOSITION OF THE TWO DIETS IN PROJECT 1 AND PROJECT 2. ........................ 51 
 
FIG 2.1 THERE WAS NO SIGNIFICANT DIFFERENCE BETWEEN APOE +/- MICE AND APOE+/- 
/GPAT1-/- MICE. ................................................................................................. 24 
FIG 2.2 GPAT1 KNOCKOUT IN APOE HETEROZYGOUS MICE REDUCED THE FAT PAD WEIGHT IN 
GONADAL ADIPOSE TISSUE. ................................................................................... 25 
FIG 2.3 APOE +/- MICE AND APOE+/- /GPAT1-/- MICE INCREASE SERUM LIPID LEVEL.   THE 
WESTERN DIET WAS PROVIDED AT 8 WEEKS TO 16 WEEKS ON APOE +/- MICE AND 
APOE+/- /GPAT1-/- MICE. ................................................................................... 26 
FIG 2.4 APOE+/- /GPAT1-/- MICE HAD MORE HDL-CHOLESTEROL.   PLASMA LIPOPROTEIN 
FRACTIONS WERE SEPARATED BY FPLC. ............................................................... 28 
FIG 2.5 LIVER TRIACYLGLYCEROL INCREASED IN APOE +/- MICE. .................................... 29 
 vii 
 
FIG 2.6 MITOCHONDRIAL GPAT ACTIVITY WAS REDUCED IN APOE+/- /GPAT1-/- MICE. ..... 30 
FIG 2.7 PAHTOLOGIC EVALUATIONS OF ARTERIAL LESIONS AND LIPID DEPOSITIONS OF THE 
AORTIC SINUS OF APOE+/- MICE AND APOE+/-/GPAT1-/- MICE FED A WESTERN DIET 
FOR 4 MONTHS. ................................................................................................... 31 
FIG 3.1 APOE+/-/GPAT1-/- MICE HAD MORE VLDL-CHOLESTEROL. ................................ 38 
FIG 3.2 PATHOLOGIC EVALUATIONS OF ARTERIAL LESIONS AND LIPID DEPOSITIONS OF THE 
AORTIC SINUS OF APOE+/- MICE AND APOE+/- /GPAT1-/- MICE FED AN ATHEROGENIC 
DIET FOR 90 DAYS. .............................................................................................. 39 
FIG 3.3 MORPHOMETRIC EVALUATION OF ATHEROSCLEROTIC LESION SIZE AT THE LEVEL OF 
THE AORTIC SINUS OF APOE+/- MICE AND APOE+/- /GPAT1-/- MICE FED AN 
ATHEROGENIC DIET FOR 90 DAYS. ......................................................................... 40 
FIG 3.4 THE MITOCHONDRIAL GPAT ACTIVITY REDUCED ON GPAT1 KNOCKOUT MICE. ...... 41 
FIG 3.5 LIVER TRIACYLGLYCEROL CONCENTRATION IN APOE +/- MICE AND APOE+/- 
/GPAT1-/- MICE FED THE ATHEROGENIC DIET FOR 90 DAYS. .................................... 42 
FIG 4.1 FXR-SHP-SREBP-1C REGULATORY CASCADE (75). ........................................ 51 
FIG 4.2 A MODEL FOR PGC-1Α TO ACTIVATE FXR AND REGULATE THE TRIACYLGLYCEROL 
METABOLISM (77). ............................................................................................... 52 
FIG 4.3 THE POSSIBLE MECHANISM HOW GPAT1 EFFECT ON ADIPOCYTE DIFFERENTIATION.
 .......................................................................................................................... 53 
 viii 
 
 
LIST OF ABBREVIATIONS 
 
ACE                   Angiotensin-converting enzyme 
APOE                  Apolipoprotein E 
CETP                  Cholesterol ester transfer protein 
CM                    Chylomicrons 
DAG                   Diacylglycerol 
HDL                    High density lipoprotein 
HNE                    4-hydroxy-2-nonenal     
FXR                    Farnesoid X receptor 
GPAT                   Glycerol-3-phosphate acyltransferase 
FAS                     Fatty acid synthesis 
FABP                   Fatty acid binding protein 
LDL                     Low density lipoprotein 
LPA                     Lysophosphatidic acid 
LPL                     Lipoprotein lipase 
LXR                    Liver X receptor 
NEM                    N-ethylmaleimide 
PC                      Phosphatidylcholine 
PE                      Phosphatidylethanolamine 
PDK     Pyruvate dehydrogenase kinase 
Pltp                     Phospholipid transfer protein 
PPAR-γ                 Peroxisome proliferator-activated receptor-γ 
SRE                    Sterol-respone element 
SHP                    Short heterodimer partner 
TGRL                   Triacylglycerol rich lipoproteins 
VLDL                    Very low density lipoprotein 
  
 ix 
 
ACKNOWLEDGEMENTS 
 
I would like to thank my advisor Dr. Coleman.  I appreciate her for giving me the 
chance to be here at the first place.  Along the way, she often provides valuable 
advice when I encounter difficulties.  On the whole, she shows me the right attitude 
toward experiments and toward sciences and she teaches me how to do research.  I 
also would like thank everyone in Dr. Coleman, especially Jessica Ellis.  I learn a lot 
of things from this lab.  I would like to thank all my friends, especially Xiaofei Mo.  
She is with me no matter what happened.  I would also like to thank my parents for 
their support and encouragement in everything I have ever decided to do.
  
 
 
 
 
  
CHAPTER 1  
Introduction 
1.1. Atherosclerosis 
Atherosclerosis is a major cause of morbidity and mortality and also the third highest 
risk factor for death in the world.  Atherosclerotic cardiovascular disease is a 
disease with multiple genetic, environmental, and other factors (1-3).  For example, 
many genes which contain encoding apolipoproteins or receptors can cause 
atherosclerosis.  The life-style, cigarette smoking and diet also play an important 
role contributing to atherosclerosis. 
 
The first animal model for studying atherosclerosis was rabbits in 1908 when 
Ignatowski (4; 5) described thickening of the intima with formation of large clear cells 
in the aorta of rabbits fed with a diet rich in animal proteins.  In recent years, mouse 
models of atherosclerosis were generated.  The apoE-deficient mice spontaneously 
develop aortic atherosclerotic plaques similar to those seen in humans (6).  The 
second mouse model of atherosclerosis, lacking the LDL receptor, was produced by 
Ishibashi et al (7).  LDL-R-/- mice develop plaques more slowly than do apoE-/- mice 
fed a chow diet.  The beginning of pathology is functional endothelial damage, 
secondary to mechanical or vascular insult, and is followed by an inflammatory 
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cascade that involves humoral and cellular mechanisms (8). 
 
The current medical treatment for atherosclerosis is aspirin, Plavix (Clopidogrel 
bisulfate) , statins (HMG-CoA reductase inhibitor) and other lowing lipid agents (9), 
capoten( ACE inhibitor), Bystolic (beta blockers), and omega-3-fatty acids.  Aspirin 
inhibits the platelet function by acetylation of the platelet cyclooxygenase (COX) and 
prevents the binding of the substrate (arachidonic acid) to the catalytic site of the 
enzyme and results in an irreversible inhibition of platelet-dependent thromboxane 
formation.  The low dose of aspirin has similar effect to high dose of aspirin (10).  
Because too much aspirin will cause gastrointestinal bleeding, doctors do not 
recommend using high dose (11).  Clopidogrel is more effective than aspirin in 
preventing atherothrombosis and causes less gastrointestinal bleeding problems 
than aspirin . 
Hyperlipoproteinaemia is also a relevant risk factor for developing atherosclerosis. 
The Heart Protection Study showed that using lipid agents reduced myocardial 
infarction, stroke and cardiovascular death and subjects needed fewer 
revascularizations (12; 13).   ACE inhibitors and beta blockers also are used to treat 
hypertension.  ACE inhibitors ameliorate endothelial function and cardiac and 
vascular remodeling and slow the progression of atherosclerosis by improving the 
ratio of PAI-1 to tPA in favor of fibrinolysis (14).  Omega-3-fatty acids have been 
demonstrated to have many cardiovascular protective effects including reducing the 
triacylglycerol content to reduce the cardiovascular disease (15).  Moreover, lifestyle 
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also plays an important role in improving atherosclerosis.  For example, regular 
exercise, diet control and smoking cessation reduces the risk of myocardial infarction 
and improves survival of patients with atherosclerosis (15; 16). 
 
1.2. Plasma lipid metabolism 
In mammals, there are two main metabolic pathways for plasma lipids: one is an 
exogenous pathway which transports dietary lipid; another is an endogenous 
pathway which transports lipid derived from the liver.  The exogenous pathway 
includes the absorption and distribution of exogenous dietary lipid.  The enterocytes 
of the small intestine absorb dietary lipids and repackage triacylglycerol, cholesterol, 
cholesterol esters, phospholipids, and fat soluble vitamins as chylomicrons.  
Chylomicrons (CM) are transported to the systemic circulation and are processed to 
chylomicron remnants by lipoprotein lipase (LPL).  This processing releases free 
fatty acid and decreases the amount of triacylglycerol in the particle, while leaving 
cholesterol ester molecules behind (17) These cholesterol ester-rich chylomicron 
remnants are removed from the plasma by the LDL receptor.  Moreover, 
chylomicrons do not only contain lipid but also contain several proteins termed 
apolipoproteins (apo).  Nascent chylomicrons contain apoB48, apoA  and apoAⅠ Ⅰ.  
When they go through the thoracic duct and enter into the circulation via the 
subclavian vein, these nascent CM particles gain apoE and the apoC`s (apoC , Ⅰ
apoC , aⅡ nd apoC ) from other plasma lipoproteins, particularly high density Ⅲ
lipoprotein (HDL) (18). 
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The endogenous pathway transports endogenously generated lipids from the liver 
through the plasma to peripheral tissue.  In humans, the hepatocytes package lipid 
into apoB100 containing VLDL particles that are secreted through the space of Disse 
into the plasma.  TAG-rich VLDL is converted by LPL in the capillaries to VLDL 
remnants (also called IDL).  VLDL remnants can then be removed from the 
circulation by peripheral tissues and the liver via the LDL receptor (19).  Alternatively, 
the VLDL remnants can be further processed by a poorly characterized mechanism 
to the highly atherogenic lipoprotein LDL (20).  These small, dense, cholesterol 
ester-rich particles do not contain apoE and can be removed by the ligand binding 
activity of ApoB100 via the LDL receptor. 
 
1.3. ApoE 
ApoE is an amphipathic protein which plays a role in lipoprotein trafficking by both 
stabilizing and solubilizing lipoprotein particles (21).  ApoE is a glycoprotein with a 
molecular size of approximately 34 KD that is synthesized in the liver, brain, and 
other tissues in both humans and mice (22).  It is part of constituent of chylomicrons, 
VLDL, IDL, and HDL and plays a role as a ligand for the receptor mediated clearance 
of these particles (6). These particles are important for “reverse-cholesterol transport” 
which lets cholesterol enter the liver via cholesterol ester transfer protein (CETP) 
from the peripheral tissues.  The cholesterol ester transfer protein plays a role in 
cholesteryl ester, triacylglycerol, retinyl ester, and phospholipids transfer activities 
and is also responsible for all of the neutral lipid transfer activity of human plasma, 
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especially from HDL to VLDL remnants (23).  Moreover, apoE is highly expressed in 
adipocytes and adipose tissue (24).  There are two mechanisms by which apoE 
affect the lipid metabolism in adipocyte.  One is that the appearance of apoE could 
accumulate the triacylglycerol because of the interaction with triacylglycerol rich 
lipoproteins (TGRLs).  Another is that exogenous apoE in VLDL is important for 
adipocyte triacylglycerol accumulation (23).  The inhibition of apoE expression could 
decrease the lipid accumulation in differentiated adipocyte.  The apoE mRNA 
concentration is also sensitive to the free cholesterol content of the adipocyte.  The 
nuclear receptors LXRα and LXRβ and their oxysterol ligands up-regulate apoE 
expression in both macrophages and adipocyte (25). 
 
1.4. Human apoE polymorphisms 
Human apoE is polymorphic and consists of three major isoforms (apoE-2, apoE-3, 
and apoE-4) of which apoE-3 is the most common.  These isoforms of apoE differ by 
their amino acid substitutions at two sites, 112 and 158 on the 299 amino acid chain.  
ApoE-2 has cysteines at both sites, apoE-4 has arginines at both sites, and apoE-3 
has a cysteine at site112 and an arginine at site158 (26).  This difference in isoform 
structure plays an important role in apoE function because the polymorphic site at 
position 158 is the region of apoE that interacts with heparin and the LDL receptor.  
This amino acid substitution in the LDL receptor binding region decreases the binding 
affinity of apoE-2 to less than 2% relative to that of apoE-3(27).  These differences 
are also associated with differing levels of risk for atherosclerosis.  Many studies 
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show that apoE-4 increases the plasma cholesterol level 2-5% while the average 
effect of possession of one apoE-2 allele is to decrease the plasma cholesterol level 
by 5-8% (28).  Because apoE-4 LDL cholesterol level compared to apoE-3 is 
increased, the increased cholesterol level in apoE-4 LDL increases the risk in 
atherosclerosis.  HDL cholesterol does not vary with the different apoE isoforms.  
Moreover, the apoE polymorphism has been found to be associated with a higher risk 
for Type Ⅲ hyperlipidemia, particularly in individuals homozygous for apoE-2.  Type 
Ⅲ hyperlipoproteinemia is a familial human condition characterized by increased 
plasma cholesterol and triacylglycerol and an increased risk of premature 
atherosclerosis. 
 
1.5. ApoE knockout mice 
In 1992 apoE-deficient mice were generated by deleting the ApoE gene by gene 
targeting (29).  Piedrahita et al. inactivated the apoE gene in mouse embryonic stem 
cells by homologous recombination.  The mice lacking apoE develop normally and 
breed normally.  Their body weights compared to wild type mice are the same.  
However, the apoE-deficient mice have significantly increased total plasma 
cholesterol levels and triacylglycerol levels in VLDL and reduced plasma high-density 
lipoprotein (30).  In apoE-/- mice, the spontaneous arterial lesions progress with time, 
as indicated by their increase in size and complexity and by their broader distribution 
in arterial lesions.  Foam cell deposits and admixes smooth muscle and free 
cholesterol comprise the atherosclerotic lesions by 5 months of age.  The arterial 
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lesions show increased complexity and the formation of fibrous caps as well as 
calcifications after 8-9 months.  The complexity of lesions in the apoE-deficient mice 
can be used as a model of human disease and make it a desirable system to study 
environmental and genetic determinants of atherosclerosis.  The study by Huang ZH 
et al.,  indicated that endogenous apoE modulates adipocyte lipid metabolism and is 
important for the effect of PPAR-γ agonists on adipocyte lipid metabolism(31).  
PPAR-γ treatment of adipocyte results in increasing apoE expression and 
triacylglycerol accumulation.  The endogenous adipocyte apoE expression also 
plays an important role in adipocyte lipid metabolism, increasing adipocyte 
triacylglycerol mass and synthesis, free fatty acid mass, cholesterol synthesis, and 
the expression of genes involved in triglyceride droplet metabolism and fatty acid 
oxidation.  The apoE knockout adipocyte reduces the gene expression of genes 
involved in fatty acid oxidation compared to wild-type adipocytes. 
 
1.6. Influence of diets on the apolipoprotein E knockout mice. 
The apoE-deficient mice generated by gene targeting have spontaneously elevated 
plasma cholesterol levels, even when fed a chow diet (4% fat, 0.022% cholesterol).  
In contrast, heterozygous apoE +/- mice did not show abnormalities in lipid 
metabolism when fed a regular chow diet, and no arterial lesions were detected in 
them (30).  Zhang et al (32) fed normal mice, heterozygous mutants and 
homozygous apoE-deficient mice with an atherogenic diet (15.8% fat, 1.25% 
cholesterol, and 0.5% cholate).  The plasma cholesterol levels increased ~2.5 fold in 
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normal mice, 3.5-fold in heterozygous mutants, and 5-fold in homozygous 
apoE-deficient mice.  The heterozygous apoE-deficient mice fed the atherogenic 
diet developed 30 times bigger atherosclerotic lesions than normal mice.  The 
atherogenic diet-induced atherosclerotic lesions in apoE-/- mice were more serious 
than apoE-/- mice fed a chow diet.  Plump et al (33) fed apoE-/- mice with a 
Western-style diet (21 % fat, 0.15 % cholesterol) and found that both their plasma 
cholesterol and their lesion area was three-fold higher than with a chow diet.   Other 
high fat diet had similar effects.  In apoE-/- mice, for example, the diet of 13% milk fat 
and 0.15% cholesterol (34) and the diet of 9% fat and 0.15% cholesterol (35) both 
increased the plasma cholesterol levels by three-fold.  A slightly modified cholesterol 
content in diet (20% fat from palm oil and 0.1% cholesterol) also can increase plasma 
cholesterol and mean lesion areas (36).  An atherogenic diet (15% cocoa butter as 
fat, 1% cholesterol and 0.5% cholic acid) induced six-fold to eight-fold increases in 
plasma cholesterol levels and lesion areas.  This atherogenic diet study (31) 
suggested that the presence of cholic acid may increase the plasma cholesterol 
levels and accelerate the development of atherosclerosis. 
 
The heterozygous apoE-deficient (apoE+/-) mice don’t develop the elevated plasma 
cholesterol levels or atherosclerotic lesion on western diet.  If apoE+/- mice are fed 
with an atherogenic diet (15.8% fat, 1.25% cholesterol. 0.5% sodium cholate), their 
plasma cholesterol levels increase ~3.5-fold compared to normal mice (32).  These 
data suggest that the apoE+/- mice respond to a particular diet to raise their plasma 
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cholesterol levels and lesions areas. 
 
However, some diets will improve the atherosclerosis in apoE-deficient mice.  
Calleja L e t al (37) showed that male apoE-/- mice respond to sunflower oils to reduce 
1/3 of the size of atherosclerotic lesions, and females respond to palm oil and olive oil 
both reduce 2-fold lesion size.  The lesion reduction in males was accompanied by a 
0.06% reduction of triacylglycerol in triacylglycerol-rich lipoproteins.  However, the 
lesion reduction in females also showed an increase of plasma apoA-I.  These data 
suggested that the development of lesions not only depends on the sex differences 
but also on the diet difference.  Black et al. (38) showed that apoE+/- mice fed an 
atherogenic diet (18.5 % triacylglycerol, 1.25 % cholesterol and 0.5 % sodium cholate) 
supplemented with 1.5g/100g palm tocopherols (palm-E) had 60% lower plasma 
cholesterol levels than mice fed the atherogenic diet alone.  In addition, when 
apoE+/- mice were fed the atherogenic diet with palm-E supplements they had smaller 
atherosclerotic lesions than mice fed the atherogenic diet alone or supplemented with 
palm carotenoids.  Ni et al. (39) also discovered that mice fed a 10% fat, 1% 
cholesterol and 0.25% cholate diet with soy protein as the protein source had smaller 
atherosclerotic lesion development than mice fed a diet with casein as the protein 
source.  Although their plasma cholesterol levels are the same, the lesion sizes in 
the thoracic aorta in the soy protein isolate group were smaller than those of the 
casein group.  This study showed that the anti-atherosclerotic effect of soy protein 
doesn’t affect serum lipids. 
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1.7. GPAT 
Acyl-CoA : glycerol-3-phosphate acyltransferase (GPAT) plays an important role in 
the de novo synthesis of TAGs.  GPAT catalyzes the acylation of 
sn-glycerol-3-phosphate to form lysophosphatidic acid (LPA) (40).  
Lysophosphatidic acid is then esterified to become phosphatidic acid which will form 
diacylglycerol and triacylglycerol (41).  In mammals, triacylglycerol can store the 
energy, supply the daily calories for humans, and serve as a precursor for the 
synthesis of phospholipids.  Triacylglycerol serves as a precursor for the synthesis 
of phospholipids in tetrahymena or for acetate-derived antibiotics in Streptomyces. 
The step of GPAT in the synthesis of triacylglycerol may be a rate limiting because 
GPAT expresses the lowest specific activity of all enzymes in this pathway (42).  
Abnormal regulation of the synthesis of triacylglycerol is associated with several 
metabolic disorders (43).  Triacylglycerol accumulation in both adipose tissues and 
nonadipose tissues causes obesity; Triacylglycerol accumulation in muscle and 
pancreas occurs with insulin resistance (44; 45) and islet cell dysfunction (46).  In 
type 2 diabetes and hepatic steatosis, the hepatic TAG and liver VLDL secretion 
increase (47; 48). 
 
1.7.1 GPAT isoforms 
There are multiple different isoforms of GPAT in mammalian tissues, two located in 
the endoplasmic reticulum (GPAT3,4), and two located in the outer mitochondrial 
membrane: GPAT1( which was previously called mtGPAT) and GPAT2 (48; 49).  The 
 11 
 
GPAT2, 3, 4 and GPAT1 also differ in their acyl-CoA substrate preference.  The 
microsomal GPAT doesn’t have a preference between saturated and unsaturated 
long-chain acyl-CoAs, but GPAT1 prefers C16:0-CoA.  GPAT1 was cloned from both 
mice and rats (50-52).  The mouse GPAT1 has 30% identity and additional 42% 
similarity to a 300-amino acid region of E.coli GPAT (51; 53).  The cDNA for mouse 
GPAT1 has an open reading frame of 827 amino acids (50; 54) The rat GPAT1 has 
89% homology and 96% identity to mouse GPAT1 and has an open reading frame of 
828 amino acids.  The mouse GPAT3 and human GPAT3 gene encode 438 and 434 
amino acid protein.  They are sharing 95% identity.  The hGPAT3 and mGPAT3 
have <15% sequence identify with mtGPAT1 (55).  GPAT4 (initially designated 
AGPAT6) was first identified in a gene-trap screen in mouse embryonic stem cells 
(56).  GPAT4 contains a cysteine (Cys-325) within a highly conserved domain 
thought to be important for G3P binding (56). 
 
1.7.2. Difference of GPAT isoforms activities 
The microsomal GPAT is sensitive to N-ethylmaleimide (NEM) which is a thiol 
reagent (57) and accounts for 80-90% of total GPAT activity in most tissues and 
50-80% of total activity in liver (58) Unlike the microsomal GPATs, GPAT1 is not 
sensitive to NEM and comprises 10% of the total GPAT activity in most tissues, but 
30%~50% of the total activity in the liver (43).  GPAT2 is competitively inhibited by 
dihydroxyacetone phosphate and polymixin B and is not stimulated by acetone.  
GPAT2 may play an important role for synthesizing mitochondrial phospholipids 
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(phosphatidylglycerol and cardiolipin) which is similar to the sole bacterial GPAT(PlsB) 
(49).  Like GPAT2, GPAT3 is sensitive to NEM, iodoacetamide, heating and acetone.  
The expression of recombinant GPAT3 increases acylation of G3P specifically, but 
not LPA, other lysophospholipids, MAG, or DAG.  Moreover, GPAT3 mRNA and 
GPAT activity in differentiated adipocytes is significantly decreased by siRNA directed 
against GPAT3 (58).  GPAT4 contributed 65% of liver NEM-sensitive GPAT specific 
activity.  GPAT4 is also the primary NEM-sensitive GPAT in BAT because the 
GPAT4-/- male mice lost the 65% NEM-sensitive GPAT activity in BAT (59). 
 
1.7.3. Fatty acid preference of different GPAT isoforms 
The other way to distinguish GPAT isoforms is by their preference for specific 
substrates.  In rat liver, kidneys and heart, GPAT1 activity is 3- to 10- fold higher with 
16:0-CoA than with 18:1-, 18:2-,18:3-, and 20:4-CoA (60; 61).   In contrast, in rat 
liver, microsomal GPAT activity is similar with 18:1-, 18:2- and 16:0-CoA (60; 61).   
Recombinant GPAT1 purified from insect cells expressed 2-fold higher activity with 
16:0-CoA than with 18:1-, 18:2n6-, 18:3n3-, or C20:4n6-CoA (62).  In contrast, 
mtGPAT2 uses 16:0-CoA as well as 18:1-CoA.  Lewin TM et al. (49) concluded that 
the microsomal GPAT does not have a preference between saturated and 
unsaturated long-chain acyl-CoAs, but GPAT1 prefers C16:0-CoA. 
 
1.8. GPAT 1 knockout mice 
GPAT1 is not necessary for embryogenesis, reproduction, or synthesis of milk TAG 
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because GPAT1-/- mice are healthy and breed normally (63).  Hammond et al. 
constructed GPAT1-/- mice and showed that female mice weighed less than controls 
and had reduced gonadal fat pad weights.   Both male and female GPAT -/- mice 
had lower hepatic triacylglycerol content, plasma triacylglycerol, and very low density 
lipoprotein triacylglycerol secretion (64). 
 
Lack of GPAT activity would prevent the directing of fatty acyl-CoAs toward 
triacylglycerol synthesis decrease competition with CPT-1 for acyl-CoAs, and 
therefore increase the oxidation of fatty acid.  When the GPAT1-/- mice were fed a 
diet high in fat and sucrose, they had two-fold higher plasma β-hydroxybutyrate and 
acyl-carnitine concentration than did control groups, and hepatic mitochondrial 
HMG-CoA synthase mRNA was upregulated (64).  Moreover, when GPAT1-/- mice 
were fed a low fat diet, their hepatic acyl-CoA content increased three-fold.  This 
demonstrated that GPAT1 plays an important role in metabolizing acyl-CoA.  GPAT1 
prefers to esterify saturated fatty acyl-CoAs, especially palmitoyl-CoA, at the sn-1 
position of glycerol-3-phosphate.  In GPAT1-/- mice, the phosphatidylethanolamine 
(PE) and phosphatidylcholine (PC) contain ~21% less palmitate and 30 and 64% 
more stearate and oleate (65).  PE and PC contain ~40% more arachidonate at the 
sn-2 position.  Arachidonate is also 21 and 67% higher in mitochondrial PE and PC 
from GPAT1-/- liver than wild-type controls.  These increases in arachidonate content 
and in fatty acid oxidation in GPAT1-/- are associated with a 20% increase in the rate 
of reactive oxygen species production, a significant increase in sensitivity to the 
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inducation of the mitochondrial permeability transition, and an increase in both 
oxidative stress-related hepatocyte apoptosis and in bromodeoxyuridine labeling (65).  
Deletion of GPAT1 protected mice from developing high-fat-diet-induced hepatic 
insulin resistance despite a large increase in hepatic acyl-CoA content (66).  A study 
described that a 90% adenovirus-mediated shRNA knockdown of hepatic 
NEM-resistant GPAT1 activity in ob/ob mice decreased liver TAG and DAG content 
40-50% and decreased plasma glucose level and plasma cholesterol level content 
30-40% (67).  The increasing of FA oxidation in the mtGPAT1 knockout mice may 
shift the balance of energy metabolism towards lipid utilization, making carbohydrate 
utilization effective to an extra load.  Therefore, mtGPAT1 knockout mice fed on high 
fat diet may ameliorate hepatic insulin sensitivity and whole body glucose tolerance.  
These studies suggested that inhibiting GPAT1 may improve atherosclerosis.  Thus, 
the goal for this project was to generate apoE+/--GPAT1-/- mice to answer the following 
questions: Do the apoE+/--GPAT1-/- mice have lower plasma triacylglycerol level and 
plasma cholesterol level than the apoE+/- mice?  Do the apoE+/-- GPAT1-/- mice 
decrease adipose tissue compared to the apoE+/-mice? Do the apoE+/-- GPAT1-/- mice 
decrease VLDL triacylglycerol secretion compared to the apoE+/- mice? Do the 
apoE+/--GPAT1-/- mice develop smaller atherosclerotic lesions than the apoE+/- mice? 
 
This study uses a western diet to induce atherosclerosis on apoE+/- mice.  As 
mentioned before, GPAT-/- mice have lower plasma triacylglycerol, hepatic 
triacylglycerol content and VLDL triacylglycerol secretion than wild type.  If we 
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generated apoE+/-- GPAT1-/- mice, we predicted that lack of GPAT in apoE+/- mice 
would ameliorate the development of atherosclerosis.  We predicted that the plasma 
triacylglycerol level and hepatic triacylglycerol level on apoE+/-- GPAT1-/- mice will be 
lower than apoE+/- mice because the GPAT is the key regulator in the synthesis of 
triacylglycerol.  We also anticipated that the size of atherosclerotic lesion on apoE+/-- 
GPAT1-/- mice would be smaller than those in apoE+/- mice because the VLDL-TAG 
secretion would be lower in the GPAT deficient mice.  This might improve the lesion 
formation.
  
 
 
 
 
  
CHAPTER 2  
Does absence of GPAT ameliorate atherosclerosis induced on apoE      
heterozygous mice fed a western diet? 
 
We fed ApoE+/- and ApoE+/-/GPAT1-/- mice a western diet for 4 months.   The ApoE-/- 
mice develop diet-induced atherosclerosis on this diet.  We wanted to see if 
ApoE+/-/GPAT1-/- mice improve the diet-induced atherosclerosis.  We tested the 
effects on both ApoE+/-/GPAT1-/- mice and ApoE+/- mice fed a western diet (consisting 
of 42% fat, 0.2% cholesterol) for 4 months.  We expected to find out that the 
ApoE+/-/GPAT1-/- mice will decrease their plasma triacylglycerol, hepatic 
triacylglycerol content, plasma cholesterol content and VLDL secretion.   Moreover, 
we hoped that we will see less atherosclerotic lesion area on the ApoE+/-/GPAT1-/- 
mice. 
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Methods 
Animals. Animal protocols were approved by the University of North Carolina at 
Chapel Hill Institutional Animal Care and Use Committee.  In experiment one, 
ApoE+/-and GPAT1+/+ heterozygous were generated by crossing the B6-backcrossed 
ApoE-/- and GPAT +/+ mice with wild type B6 animals.  ApoE +/- and GPAT1-/- 
heterozygous were generated by crossing the B6-backcrossed ApoE-/- and GPAT1-/- 
mice with GPAT1-/- mice.  In experiment 1 (Chapter2), after 8 weeks of age, animals 
were fed on a western diet containing 0.2 % cholesterol and providing 42 % calories 
as fat (milkfat) (TD88137; Harlan Teklad, Madison Wisconsin, USA) for four months.  
Mice were weighed at the beginning of diet (d 0) and the end (d 120) of the diets.  In 
experiment 2 (Chapter 3), after 8 weeks of age, animals were fed on a atherogenic 
diet containing 18.5 % fat, 1.25 % cholesterol, and 0.5 % cholate (TD88051; Harlan 
Teklad, Madison Wisconsin, USA) for three months.  Mice were weighed at the 
beginning of diet (d 0) and the end (d 90) of the diets. 
Plasma lipid assay Blood samples were collected from animals fasted 4 hours by 
retroorbital bleeding into a tube containing EDTA at d 0, d 60 and d 120.   The blood 
was centrifuged for 10 min at 12,000 x g at 4℃.  Plasma was measured for 
triacylglycerol (GPO-Trinder kit, #339-20, Sigma Chemical) , cholesterol (Cholesterol 
CⅡ kit, #276-64909, Wako Pure Chemical, Osaka, Japan) and glucose (Glucose 
Trinder; sigma) using colorimetric enzyme methods. 
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Lipoprotein separation Plasma lipoproteins were separated by density using 
FPLC system (Amersham Pharmacia Biotech, Piscataway, NJ).  The system 
fractionated serum lipoprotein by superpose-6 gel column (Pharmacia) which was 
equilibrated at 0.5 ml/min with running buffer (PBS containing 20 g sodium azide/L).  
Then 100 µL of mouse serum collected from four mice in one experimental group was 
injected onto the column.  The sample was run at 0.4 mL/min, and 0.5 mL fractions 
were collected.  After discarding the first 10 fractions, the rest of the fractions were 
assayed for total cholesterol and 
triacylglycerol as above. 
 
Morphometric analysis Mice fasted for 4h were sacrificed with an overdose of 
Avertin.  The hearts were perfused with phosphate-buffered paraformaldehyde (4%) 
under physiological pressure.  Segments of the proximal aorta and the portion of the 
heart containing the aortic sinus were embedded, sectioned, stained with Sudan IVB 
(Fisher Scientific Co., Milwaukee, WI), and counterstained with hematoxylin.  The 
sections stained with hematoxylin and eosins were used for histological evaluations.   
Average lesion sizes of four sections were used for the morphometric evaluations to 
represent the lesion size of each animal.   Morphometry evaluation of the lesion 
size was conducted using Image measure/IP IM 2500 Morphometry system (Phoenix 
Technology, Federal Way, MA)(32) 
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mRNA analyses RNA was extracted from liver and fat pads that had been 
flash-frozen in liquid nitrogen.   Total RNA was extracted by using TRIzol reagent 
(Invitrogen) according to the manufacturer’s instructions.   After 1.5 µg of total RNA 
were reverse transcribed with an oligo-prime, PCR was performed with a DNA 
Engine Opticon 2 System using SYBR green QPCR dye kit (Stratagene). 
 
Liver lipids Unperfused liver was removed and flash-frozen in liquid nitrogen.   
Approximately 0.1 g each of liver samples was homogenized and extracted with 
chloroform: methanol (2:1v/v) (68).  To measure cholesterol and triacylglyceride, 
lipid aliquots were resuspended in 0.2 mL 10% Triton X-100 in isopropanol before 
measurement 
 
Total particulate preparations and enzyme assays Livers were sliced into Medium 
1 (250 mM sucrose, 10 mM Tris, PH 7.4, 1 mM EDTA, 1 mM dithiothreitol) , 
homogenized with 15 up-and-down strokes in a motorized Teflon-glass homogenizing 
vessel, and centrifuged at 100,000 x g for 1 h to obtain total particulate fractions.  
GPAT activity was assayed in a 200-µl mixture containing 75 mM Tris-HCL, pH 7.5, 4 
mM MgCl2, 1 mg/ml bovine serum albumin (essentially fatty acid-free ), 1 mM 
dithiothreitol, 8 mM NaF, 800 µM [H3] glycerol 3-phosphate, and 80 µM palmitoyl-CoA.  
The reaction was started by adding 15-30 µg of protein to the assay mix.  All assays 
were performed for 10 min at room temperature. 
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Result and Discussion 
ApoE+/-- GPAT1-/- mice had slightly reduced body weight.  Because female 
GPAT1-/- mice have reduced 16% of body weight compared to wild type mice when 
they were 6 month-old (64), we predicted that apoE+/-- GPAT1-/- mice and GPAT1-/- 
mice might have reduced body weight.  ApoE+/-- GPAT1-/- mice weighed 14% less 
than apoE+/-mice after 4 months of western diet but the difference was not significant 
(Figure 2.1).  To investigate whether adipose tissue from apoE+/-- GPAT1-/- mice and 
GPAT1-/- mice was decreased, we isolated fat pads from these animals.  Fat pads 
from ApoE+/-- GPAT1-/- mice had 51% smaller gonadal fat pads than apoE+/-mice 
(Figure 2.2).  Thus, the reason for slightly reduced body weight could be the smaller 
fat pads. 
 
ApoE+/-- GPAT1-/- mice had reduced plasma lipids compared apoE+/-mice.   In 
female mice fed the western diet for 120 days, the plasma cholesterol concentration 
of apoE+/- mice was 27% higher than apoE+/-- GPAT1-/- mice (Figure 2.3).  But, the 
concentrations of plasma cholesterol of the two groups were lower than lipid levels 
that would cause atherosclerosis.  In a study by Zhang SH, which fed apoE 
heterozygous mice on an atherogenic diet for 12 weeks, plasma cholesterol level was 
326 ± 153 (32).  Because GPAT1-/- mice had lower plasma triacylglycerol and 
VLDL-triacylglycerol secretion than wild type mice, we expected to see a reduction of 
plasma triacylglycerol in the apoE+/-- GPAT1-/- mice.  The concentration of plasma 
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triacylglycerol of ApoE+/-- GPAT1-/- mice was 53% lower than apoE+/-mice. 
 
FPLC analysis of lipoproteins.   When mice were fed the western diet, the major 
cholesterol containing fraction was HDL (fractions 28-34).  ApoE+/- mice had a 
higher peak of HDL than the apoE+/-- GPAT1-/- mice.  ApoE+/-- GPAT1-/- mice had 
higher peak of VLDL than the apoE+/- mice (Figure 2.4).  So, apoE+/-- GPAT1-/- mice 
might get atherosclerosis because most of the cholesterol in the apoE-deficient mice 
was carried by particles with sizes in the VLDL to IDL range (32).  However, when 
high plasma lipids induce atherosclerosis in mice, the major cholesterol containing 
fraction is VLDL instead of HDL (38).  These authors showed that when apoE +/- 
mice were fed the nonpurified control diet, the major lipoprotein peak was HDL. 
 
ApoE+/-- GPAT1-/- mice had lower hepatic triacylglycerol.  We examined liver 
histology and analyzed liver lipid.  In apoE+/-- GPAT1-/- mice, hepatic triacylglycerol 
concentration was 30% lower than apoE+/- mice (Figure 2.5).   This is consistent 
with the reduction of GPAT1 activity in the liver which contributes to triacylglycerol 
synthesis.  Our study showed that hepatic triacylglycerol concentration of female 
GPAT -/- mice was 36% lower than female wild-type mice at the 2 month of age.  
These data were similar to the data we found from the apoE+/- mice and apoE+/-- 
GPAT1-/- mice. 
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Histological and morphometric analysis of arterial lesions.  To investigate 
whether lack of GPAT1 can protect against the development of atherosclerosis, the 
lesion area was assessed at the aortic sinus, the arch, the third intercostals branch 
and the celiac branch.  The atherosclerotic lesions were measured at all four sites.  
There were no atherosclerotic lesions in apoE+/- mice or apoE+/-- GPAT1-/- mice.  
This is consistent with the lower content of plasma cholesterol and the main peak of 
HDL-cholesterol.  Although Plump et al. fed apoE-deficient mice for 4-5 weeks with 
a western-style diet (21% fat, and 0.15% cholesterol by weight), they found out that 
the lesion sizes were three times larger than those on normal diet (69). 
 
Thus, after being fed 120 days with a western diet, there were no atherosclerotic 
lesions in apoE+/-mice or apoE+/-- GPAT1-/- mice.  The plasma cholesterol was low in 
both groups of mice.  The highest peak of cholesterol fraction was HDL.  These 
data showed the western diet cannot induce atherosclerosis in apoE+/-mice or 
apoE+/-- GPAT1-/- mice. 
 
Although apoE+/-- GPAT1-/- mice decrease 14% body weight, 27% of plasma 
cholesterol, 53% of plasma triacylglycerol, and 30% of hepatic triacylglycerol 
compared to apoE+/- mice.  There were no atherosclerotic lesions.  Thus, we could 
not conclude that absence of GPAT could improve the atherosclerosis. 
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Tab 2.1 Weight and plasma triacylglycerol and plasma cholesterol in ApoE +/- 
female mice and ApoE+/- /GPAT1-/- female mice fed on western diets for 120 
days. 
Data are presented as mean±SE.   For all initial groups, n=8 for all group.   For 
final groups, n=8 for Ee/GG mice, n=6 for Ee/gg mcie.  Superscripts “a” indicate 
significant differences between changes in Ee/GG mice and Ee/gg mice (p<0.05).   
Ee/GG indicates apoE+/- female mice, Ee/gg indicates apoE+/-/GPAT1-/- mice. 
 
 
 
 
 Ee/GG Ee/gg 
Final weight(g) 33.3±2.2 28.8±1.8 
Adipose 
tissue/body 
weight (%) 
(inguinal) 
2.1±0.3 1.8±0.3 
(Gonadal) 7.7±0.4 3.1±1.0 
Initial TAG 
(mg/dL) 
32.1±3.7 16.8±6.6 a 
Final TAG 
(mg/dL) 
48.8±10.9 23.1±3.3 
Initial cholesterol 
(mg/dL) 
40.2±2.8 44.1±2.1 
Final Cholesterol 
(mg/dL) 
112.5±9.0 81.6±6.9 a 
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Fig 2.1 There was no significant difference between ApoE +/- mice and ApoE+/- 
/GPAT1-/- mice. 
The western diet fed from at 8 weeks to 16 weeks on ApoE +/- mice and ApoE+/- 
/GPAT1-/- mice.   There was no significant different between ApoE +/- mice and 
ApoE+/- /GPAT1-/- mice. 
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Fig 2.2 GPAT1 knockout in apoE heterozygous mice reduced the fat pad weight 
in gonadal adipose tissue. 
The western diet was provided at 8 weeks to 16 weeks on ApoE +/- mice and ApoE+/- 
/GPAT1-/- mice.  *P<0.05 
 
 
 
 
 
 
  
  
Fig 2.3 ApoE +/- mice and ApoE+/
The western diet was provided at 8 weeks to 16 weeks on ApoE +/
ApoE+/- /GPAT1-/- mice.
Serum was obtained in animals at the age of 8 weeks on a chow diet (weeks=0)
Mice were started on a western diet and obtained serum at 4 months
were assayed for Cholesterol (A), and Triglycerides (B)
 
(A) Cholesterol 
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(B) Triacylglycerol 
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Fig 2.4 ApoE+/- /GPAT1-/- mice had more HDL-cholesterol.   Plasma 
lipoprotein fractions were separated by FPLC. 
Cholesterol in each fast-protein liquid chromatography fraction (0.5mL) from plasma 
(100 L ) of ApoE +/- mice (filled diamond) and ApoE+/- /GPAT1-/- mice (filled squares).  
Each “N” indicates three pooled sample. 
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Fig 2.5 Liver triacylglycerol increased in ApoE +/- mice. 
The western diet was provided at 8 weeks to 16 weeks on ApoE +/- mice and ApoE+/- 
/GPAT-/- mice.   Results are expressed as mean ±SE.   ** P<0.01 
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Fig 2.6 Mitochondrial GPAT activity was reduced in ApoE+/
GPAT- specific activity was determined in animal tissue from ApoE 
ApoE+/- /GPAT1-/- mice as described under “Experimental Procedures.”
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CHAPTER 3  
Does absence of GPAT1 ameliorate atherosclerosis induced on apoE 
heterozygous mice fed an atherogenic diet? 
 
We fed ApoE+/-and ApoE+/-/GPAT1-/- mice on a western diet for 4 months because we 
hypothesized that lack of GPAT1 would improve the atherosclerosis which was 
induced by western diet.  However, the apoE heterozygous mice didn’t develop 
diet-induced atherosclerosis when fed a western diet.   Therefore, we changed to 
another kind of diet to develop diet-induced atherosclerosis.  According to the study 
by Black et al., the atherogenic diet will cause ApoE heterozygous mice to develop 
atherosclerosis in 90 days.  Therefore, we fed ApoE+/- and ApoE+/-/GPAT1-/-mice on 
the atherogenic diet (15.8% fat, 1.25% cholesterol, 0.5% cholate) for 90 days.  We 
wanted to see if ApoE+/-/GPAT1-/- mice have less diet-induced atherosclerosis than 
the ApoE+/-mice.  We expected to find that the ApoE+/-/GPAT1-/- mice had lowered 
their plasma triacylglycerol, hepatic triacylglycerol content, plasma cholesterol 
content. 
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Result and Discussion 
 
ApoE+/-- GPAT1-/- mice have reduced body weight.  Because female GPAT1-/- 
mice have reduced body weight compared to wild type mice, we predicted that 
apoE+/-- GPAT1-/- mice and GPAT1-/- mice would have reduced body weight.  After 3 
months of the atherogenic diet, ApoE+/-- GPAT1-/- mice weighed 16% less than 
apoE+/-mice and 14% less than GPAT1-/- mice (Table 3.1).   Although GPAT1-/- mice 
had lower body weight than wild type mice (64), the weight of GPAT1-/- mice was 
similar to that of the apoE+/-mice.  To determine whether the difference in weight of 
the ApoE+/-- GPAT1-/- mice was due to a difference in adipose tissue mass, we 
isolated fat pads from these animals.   ApoE+/-- GPAT1-/- mice had 61% smaller 
inguinal fat pads compared to apoE+/-mice and 42% smaller inguinal fat pads 
compared to GPAT1-/- mice.   ApoE+/-- GPAT1-/- mice had 66% smaller gonadal fat 
pads compared to apoE+/-mice and 36% smaller gonadal fat pads compared to 
GPAT1-/- mice.   Thus, the reason of reduced body weight would be smaller fat 
pads. 
 
ApoE+/-- GPAT1-/- mice didn’t change plasma lipids.  In mice fed the atherogenic 
diet for 90 days, the plasma cholesterol concentration of apoE+/-- GPAT1-/- mice was 
39% higher than apoE+/- mice (Table 3.1), but because the values were variable, the 
difference was not significant.  The plasma cholesterol concentration of apoE+/-- 
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GPAT1-/- mice was 40% greater than in the GPAT1-/- mice.  Because GPAT1-/- mice 
have reduced plasma triacylglycerol and VLDL-triacylglycerol secretion compared to 
wild type mice, we expected to observe a lower plasma triacylglycerol concentration 
in both apoE+/-- GPAT1-/- mice and GPAT1-/- mice.  However, the plasma 
triacylglycerol concentrations were not different between apoE+/- mice and apoE+/-- 
GPAT1-/- mice.  The plasma triacylglycerol concentrations were also not different 
between apoE+/-- GPAT1-/- mice and GPAT1-/- mice. 
 
FPLC analysis of lipoproteins.  When mice were fed the atherogenic diet, the 
major cholesterol containing fractions were VLDL (fractions 14-17), intermediate 
density lipoprotein (IDL) (fractions 17-19), and LDL (fractions 19-27), whereas the 
HDL peak decreased.  ApoE+/-- GPAT1-/- mice had a greater area under the curve for 
VLDL, IDL and LDL than the apoE+/-mice (Figure 3.1).  This was consistent with the 
increased serum cholesterol in apoE+/-- GPAT1-/- mice compared to apoE+/- mice.  
These data suggest that lack of GPAT increases serum VLDL-cholesterol. 
 
Histological and morphometric analysis of arterial lesions.  To investigate 
whether absence of GPAT has the potential to protect against the development of 
atherosclerosis, the lesion area was assessed at the arch, third intercostals branch 
and celiac branch.  There was no significant difference in lesion size between 
apoE+/-- mice and apoE+/-- GPAT1-/- mice.   The average atherosclerotic lesion size 
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of apoE+/- mice was 154,161±19,976 µM2 (Figure 3.2).  The average atherosclerotic 
lesion of apoE+/-- GPAT1-/- mice was 213,743 ± 86,896 µM2.  Although the average 
atherosclerotic lesion of apoE+/-- GPAT1-/- mice was 30% greater than apoE+/-mice, 
there was no significant difference between two groups.  These data showed that 
lack of GPAT1 did not lessen the extent of atherosclerosis. 
 
Hepatic lipid.   The livers of the mice fed the atherogenic diet were pale and fatty.  
We examined liver histology and analyzed liver lipid.  In apoE+/-- GPAT1-/- mice, the 
hepatic triacylglycerol concentration was 14% lower than apoE+/- mice, but there was 
no significant difference between groups (Figure 3.3).   In GPAT1-/- mice, the 
hepatic triacylglycerol concentration was 49% lower than apoE+/-- GPAT1-/- mice and 
53% lower than apoE+/- mice, consistent with the reduction of mitochondrial GPAT 
activity in the liver which is the rate-limiting enzyme of triacylglycerol synthesis.  
However, we did not find this consistent by in the apoE+/-- GPAT1-/- mice which had 
similar hepatic triacylglycerol with apoE+/- mice in the liver.  Although apoE+/-- 
GPAT1-/- mice had 75% less mitochondrial GPAT activity compared to apoE+/- mice, 
the hepatic triacylglycerol of apoE+/-- GPAT1-/- mice was similar with apoE+/- mice. 
 
We concluded that apoE+/-- GPAT1-/- mice reduced body weight compared to apoE+/- 
mice and GPAT1-/- mice.  Because female GPAT1-/- mice have reduced 16% of body 
weight compared to wild type mice when they were 6 month-old (64),  we expected 
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to see lower body weight in GPAT1-/- mice than in apoE+/- mice.  However, the body 
weight of GPAT1-/- mice was similar to apoE+/- mice.  The fat pads of apoE+/-- 
GPAT1-/- mice were very small.  As in the previous chapter, the apoE+/-- GPAT1-/- 
mice had smaller the fat pads compared to apoE+/- mice on the western diet.  The 
reason for small fat pads in apoE+/-- GPAT1-/- mice could be lack of both apoE and 
GPAT expression (64; 70).  Although there was no difference of plasma cholesterol 
between apoE+/- mice and apoE+/-- GPAT1-/- mice, the cholesterol of apoE+/-- GPAT1-/- 
mice had the highest area under the curve for VLDL, IDL, and LDL.  We speculated 
that apoE+/-- GPAT1-/- mice maybe increase the atherosclerotic lesion size. 
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Tab 3.1 Weight and plasma triacylglycerol and plasma cholesterol in ApoE +/- 
mice, ApoE+/- /GPAT1-/- mice and GPAT1-/- female mice fed on atherogenic 
diets for 90 days. 
Data are presented as mean ± SE.   For all initial groups, n=11 for all group.   For 
final groups, n=9 for Ee/GG mice, n=10 for Ee/gg mcie, and n=11 for gg mice.   
Superscripts “a” indicate significant differences between changes in Ee/GG mice and 
Ee/gg mice (P<0.05).   Superscripts “b” indicate significant differences between 
changes in Ee/gg mice and gg mice (P<0.05).   Ee/GG indicates apoE+/- female 
mice, Ee/gg indicates apoE+/-/GPAT1-/- mice and gg indicates GPAT1-/- female mice. 
 
 
 
 
 Ee/GG Ee/gg gg 
Final weight(g) 23.6±0.6 19.9±0.7 a, b 23.2±0.5 
Adipose 
tissue/body weight 
(%) (inguinal) 
1.1±0.1 0.4±0.1 a, b 0.7±0.1 a, b 
(Gonadal) 1.1±0.1 0.38±0.1 a, b 0.6±0.1 
Initial TAG (mg/dL) 46.2±3.3 34.7±2.8 27.7±1.5 
Final TAG (mg/dL) 12.66±2.0 13.2±4.2 10.5±0.6 
Initial cholesterol 
(mg/dL) 
47.8±6.2 82±12.3 54.5±1.4 
Final Cholesterol 
(mg/dL) 
244.2±15.3 401.5±82.6 242.7±11.9 b 
 
  
  
Fig 3.1 ApoE+/-/GPAT1
Cholesterol in each fast
(100µL) of ApoE +/- mice (unfilled circle), ApoE
GPAT1-/- mice (filled diamond).   The ApoE
VLDL-Cholesterol as the ApoE
HDL-Cholesterol than the ApoE
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-/- mice had more VLDL-cholesterol. 
-protein liquid chromatography fraction (0.5mL) from plasma 
+/-
 /GPAT1-/- mice (filled squares) and 
+/-/GPAT1-/- mice have similar 
+/-
 mice.   The GPAT1-/- mice have higher peak of 
+/-/GPAT1-/- mice and ApoE+/- mice.
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Fig 3.2 Pathologic evaluations of arterial lesions and lipid depositions of the 
aortic sinus of ApoE+/- mice and ApoE+/- /GPAT1-/- mice fed an atherogenic 
diet for 90 days. 
Cryosectioned tissue was stained with Sudan IV and counterstained with hematoxylin.  
“A” presented the aortic sinus of ApoE+/- mice.  “B” presented the aortic sinus of 
ApoE+/- /GPAT1-/- mice. 
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Fig 3.3 Morphometric evaluation of atherosclerotic lesion size at the level of the 
aortic sinus of ApoE+/- mice and ApoE+/- /GPAT1-/- mice fed an atherogenic 
diet for 90 days. 
Each point represents the mean lesion size of three sections measured in each 
mouse. 
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Fig 3.4 The mitochondrial GPAT activity reduced on GPAT1 knockout mice. 
GPAT- specific activity was determined in animal tissue from ApoE +/- mice and 
ApoE+/- /GPAT1-/- mice as described under “Experimental Procedures.” 
(** P<0.01) 
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Fig 3.5 Liver triacylglycerol concentration in ApoE +/- mice and ApoE+/- 
/GPAT1-/- mice fed the atherogenic diet for 90 days. 
Liver from the ApoE+/- mice has similar content of hepatic TAG with the 
ApoE+/-/GPAT1-/- mice.  But, the GPAT1-/- mice have 49% less content of hepatic 
TAG than ApoE+/- /GPAT1-/- mice.   (** P<0.01) 
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CHAPTER 4  
Discussion 
The major finding of this study was that lack of GPAT1 did not diminish 
atherosclerosis that was induced by diet in apoE+/- mice.  GPAT1 is the key enzyme 
that controls triacylglycerol synthesis and is also up- regulated by SREBP-1c when 
lipogenesis is enhanced.   Although apoE+/--GPAT1-/- mice had an increase in the 
plasma cholesterol, it was not significant.  The lesion size of apoE+/--GPAT1-/- mice 
was also similar to apoE+/- mice.  These results indicated that a knockout of GPAT1 
did not improve the atherosclerosis. 
 
Atherosclerosis 
The ideal model to investigate whether the GPAT knockout does improve the 
atherosclerosis would be to use apoE-/- mice.  ApoE-/- mice develop atherosclerosis 
spontaneously, so use of apoE-/- could exclude the diet effect on the study.  Because 
of difficulties in the production of double knockout mice, we decided to use 
apoE+/--GPAT1-/- mice.  When we fed a western diet, ApoE+/- mice and 
ApoE+/-/GPAT1-/- mice did not develop atherosclerosis.  Reasons why the apoE+/- 
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mice and apoE+/--GPAT1-/- mice did not develop atherosclerosis may be that the 
western diet lacks cholate in the diet and contains a low content of cholesterol.  
When we fed the mice on the atherogenic diet, there was no difference on lesion size 
in ApoE+/- mice and ApoE+/-/GPAT1-/- mice.  The composition of atherogenic diet is 
cholesterol plus cholate.  One study showed that cholesterol and cholate 
components of the atherogenic diet have distinct proatherogenic effects and 
contribute to the acute inflammatory response and fibrogenesis independently 
through the different (71).  In this study, the authors fed male C57BL/6J mice on five 
different kinds of diets: chow, atherogenic diet, no cholate, no cholesterol, and no fat.  
Then, they did microarrays on the liver samples and found that cholate induced 
phospholipids transfer protein (pltp) which is involved in lipoprotein remodeling.   
The cholate also induced liver X receptor-β, an oxysterol-binding nuclear hormone 
receptor that activates several genes involved in cellular cholesterol efflux.  Another 
study on female Zucker rats showed that dietary cholesterol plus cholate 
down-regulated hepatic lipase (H-TGL).  H-TGL facilitates the transfer of cholesterol 
from IDL to LDL back to the liver (72).   The reduction of H-TGL expression was 
related to a increase in cholesteryl ester in the liver.  So, the diet contains cholate 
would increase liver cholesteryl ester content.  The cholic acid also activates FXR to 
down-regulate the cholesterol 7α-hydroxylase mRNA in C57BL/6 mice (73).   When 
these investigators fed cholic acid to mice, serum LDL and VLDL cholesterol and 
hepatic cholesterol increased, and the serum triacylglycerol concentration decreased.    
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These results from (73) were similar to our results.  Further, the serum triacylglycerol 
content of mice fed on atherogenic diet was lower than on western diet.  Our results 
are consistent with a study showing that the addition of sodium cholate prevents a 
high-fat diet from inducing triacylglycerol accumulation because the cholate down 
regulates acyl-CoA synthetase1 mRNA through its sterol-response element-1(SRE-1) 
(74).  Watanabe M et al. showed that increasing the bile acid pool size increases the 
activation of farnesoid X receptor (FXR), and increases short heterodimer partner 
(SHP) levels which, in turn, reduce SREBP-1c expression (75).  The reduction of 
SREBP-1c would decrease triacylglycerol synthesis (Figure 4.1) (75).  The possible 
mechanism for reduced triacylglycerol synthesis could be this FXR-mediated 
reduction of plasma triacylglycerol content which may occur via FXR-mediated 
up-regulation of pyruvate dehydrogenase kinase (PDK4) which enhances the 
utilization of fat rather than glucose as an energy source (76).  Another possible 
mechanism for the reduction of serum triacylglycerol could be that PGC-1α 
decreases SREBP-1c by increasing the FXR pathway (Figure 2) (77).  In this in vitro 
study with fasting mice, increased hepatic expression of PGC-1α and FXR resulted in 
a decrease in plasma triacylglycerol. 
 
Oxidative stress and atherosclerosis 
What causes the apoE+/--GPAT1-/- mice have to a similar aortic lesion sizes despite a 
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higher plasma cholesterol concentration?  The atherogenic diet will increase 
lipid-induced oxidative stress, which could cause steatohepatitis and atherosclerosis.  
From the Haematoxylin & Eosin stain of the liver, we could see the cellular ballooning 
and couldn’t see the original structure of liver lobule.  Matsuzawa N et al. have 
reported that the atherogenic diet up-regulates the hepatic expression levels of genes 
for fatty acid synthesis (SREBP-1c which is a transcriptional regulator of fatty acid 
synthesis, and fatty acid synthase), oxidative stress, inflammation (electron-transport 
chain, p38 MAPK signaling pathway, and the FAS pathway and stress induction), and 
fibrogenesis (transforming growth factor β signaling pathway and matrix 
metalloproteinase) (78).  These authors showed that male C57B1/6J mice fed the 
atherogenic diet for 24 weeks had more 4-hydroxy-2-nonenal and hepatic protein 
carbonyls in their liver.  4-HNE is a major aldehyde end-product of membrane lipid 
peroxidation due to oxidative stress and protein carbonyls are another marker of 
oxidative stress.  Moreover, the reason that apoE+/--GPAT1-/- mice have similar 
lesion sizes is that maybe the knockdown of GPAT1 cause more oxidative stress.  
Hammond et al. showed that GPAT1 deficient livers have increased oxidative stress 
and apoptosis (65).  The GPAT1-/- livers had more 4-hydroxy-2-nonenal density than 
wild-type mice in both young and old mice.  Further, oxidative stress increases 
oxidized low-density lipoprotein which is an important factor in the development of 
atherosclerosis (79).  Thus, the apoE+/--GPAT1-/- mice may have similar lesion sizes 
because GPAT1 knockout livers have more oxidative stress. 
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Adipose tissue effect 
The other major finding of this study was that ApoE+/-- GPAT1-/- mice had 61% smaller 
inguinal fat pads than apoE+/-mice and 42% smaller inguinal fat pads than GPAT1-/- 
mice on the atherogenic diet.  ApoE+/-- GPAT1-/- mice had 66% smaller gonadal fat 
pads than apoE+/-mice and 36% smaller gonadal fat pads than GPAT1-/- mice on 
atherogenic diet.  We also found a similar result for mice fed the western diet.  The 
possible reasons of ApoE+/-- GPAT1-/- mice had smaller fat pads than ApoE+/- mice or 
GPAT1 -/- mice are unclear.  ApoE plays an important role in adipose tissue.  ApoE 
is highly expressed in adipocytes and its expression is up-regulated by PPAR-γ and 
tumor necrosis factor-α.  Huang HZ et al., showed that apoE knockout mice have 
smaller fat pads and smaller adipocytes compared to wild-type mice (31).  They also 
isolated adipocytes from ApoE -/- mice and wild-type mice.  The adipocytes of ApoE 
-/- mice contained less triacylglycerol than the adipocytes from wild-type mice.  They 
concluded from these results that ApoE modulates adipocyte lipid metabolism and is 
important for the effect of PPAR-γ agonists on adipocyte lipid metabolism.   Another 
study showed that obese leptin deficient (ob/ob) mice suppress adipose tissue ApoE 
expression.  When they transplanted bone marrow with or without ApoE into ob/ob 
mice, the ob/ob; ApoE+/+ mice had over-10 fold lower atherosclerotic lesion area than 
ob/ob; ApoE-/- mice (80; 81).  Recipients of ApoE+/+ marrow demonstrated 3.7-fold 
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plasma cholesterol and 1.7-fold lower plasma triacylglycerol concentration than ob/ob; 
ApoE-/- mice. 
 
On the GPAT side, GPAT1 controls the pathway of triacylglycerol synthesis.  When 
GPAT1 is absent in liver, lysophosphatidic acid (LPA) decreases (Coleman 
unpublished) so a reduction of LPA might down-regulate PPAR-γ.  LPA was shown 
to down-regulate in the PPAR-γ in 3T3F442A cell line, which can differentiate into 
adipocytes when cultured in an appropriate adipogenic medium (82).  LXR 
expression is regulated by PPAR-γ in adipocytes (83).  These authors treated 
C57BL/6 mice with T0901317, an activator of LXR, and increased the expression of 
lipogenic genes LXRα, FAS, SREBP-1c, PPAR-γ and aP2.  In the LXRα knockdown 
adipocytes, adipocyte-specific gene expression, including PPAR-γ and aP2, is 
inhibited.  However, LXRα activation of PPAR-γ deficient MEF cells showed that the 
LXRα activation cannot induce adipogenesis without PPAR-γ.  Another study 
showed that LXRs play an important role in mediating fat metabolism and the control 
of lipid storage capacity in mature adipocytes (84).  When LXR-α is expressed in 
obese Zucker rats treated with thiazolidinediones, the PPAR-γ target gene Fatty acid 
binding protein (FABP) increases.  In our study, ApoE+/-- GPAT1-/- mice lack GPAT1 
in liver and may decrease LPA synthesis.  The reduction of LPA synthesis in 
adipocyte might decrease the PPAR-γ activation which would reduce the induction of 
LXR expression for adipocyte differentiation.  Moreover, ApoE+/-- GPAT1-/- mice lack 
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ApoE expression and ApoE is also required for adipocyte differentiation (Figure4.3).  
Thus, lack of ApoE and GPAT1 might result in smaller fats pad. 
 
On the diet side, there are many studies feeding an atherogenic diet and decreasing 
the fat pads.  But, the mechanism of reduction fat pads is unclear.  For example, 
when wild-type mice are fed an atherogenic diet for 12 weeks, epididymal fat pad 
weights decreased 64% compared to mice fed a control diet (78).  Another study 
showed that C57BL/6J female mice fed high-oleic safflower oil plus cholate and 
cholesterol decrease 85% of the WAT weight compared to mice fed the same diet 
without added cholate and cholesterol (74).  These authors did not investigate the 
reasons why fat pad weights decrease on the atherogenic diet. 
 
In conclusion, we believe that the ApoE+/-- GPAT1-/- mice had the smallest fat pad 
because knockout GPAT1 would down regulate the PPAR-γ and LXR and thus 
decrease adipocyte differentiation.  Because ApoE also controls the adipocyte 
differentiation, GPAT1-/- mice had larger fat pads than ApoE+/-- GPAT1-/- mice. 
 
Future studies.  We will want to see if absence of GPAT1 ameliorates 
atherosclerosis in ApoE-/- mice.  ApoE-/- mice develop atherosclerosis spontaneously.  
Without feeding an atherogenic diet, we could exclude the effect of atherogenic diet 
on atherosclerosis (such as activation of FXR and LXR).  Moreover, we could 
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exclude the atherogenic diet as a cause of the reduction of fat pad weight.  This 
would be the best model to investigate whether the absence of GPAT1 improves 
atherosclerosis or not. 
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Tab 4.1 Composition of the two diets in project 1 and project 2. 
 
 
 
 
 Western diet Atherogenic diet 
Protein 17.3% 19.7% 
Carbohydrate 48.5% 40.7% 
Fat (source) 21.2% (Anhydrous 
milkfat) 
15.8% (Coca butter) 
Cholesterol 0.2% 1.25% 
Cholate 0 0.5% 
 
Fig 4.1 FXR-SHP-SREBP-1c regulatory cascade (75). 
The cholate in the atherogenic diet would increase the FXR.  FXR would 
increase SHP which decreases the expression of SREBP-1c. The 
reduction of SREBP-1c would decrease triacylglycerol synthesis in the 
liver. 
 
 
  
Fig 4.2 A Model for PGC
metabolism (77). 
The fasting would increase PGC
promoter to induce FXR ex
reduce the expression of SREBP
synthesis. These could be the reason why atherogenic diet decreases 
the serum triacylglycerol content.
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Fig 4.3 The possible mechanism how GPAT1 effect on adipocyte differentiation. 
When absence of GPAT 1 would decrease the LPA, LPA would 
down-regulate the PPAR-γ. LXR stimulate adipocyte differentiation 
through induction of PPAR-γ expression. LXR also up-regulates ApoE 
expression in adipocytes. 
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